Skip to Content

Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming ENDO Meeting

QUÉBEC CITY, June 14, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that Jose M. Garcia, MD, PhD, of the Baylor College of Medicine and the Michael E. DeBakey VA Medical Center in Houston, Texas, will be making an oral presentation on Phase 3 results for AEZS-130 as an oral diagnostic test for Adult Growth Hormone Deficiency (AGHD), at the 94th ENDO Annual Meeting and Expo which will be held June 23-26, 2012, in Houston.

Abstract #584:  "AEZS-130 (Macimorelin) - Stimulated GH Test: Validation of a Novel Test for the Diagnosis of Adult Growth Hormone Deficiency (AGHD)", J. M. Garcia, R. Swerdloff, C. Wang, M. Kyle, M. Kipnes, B. Biller, D. Cook, K. Yuen, V. Bonert, A. Dobs, M. Molitch, G. Merriam. 
Date and time:  Monday, June 25, 2012, at 11:15 am (Central) 
Session:   CLINICAL − What's New in Diagnosis & Treatment of GH Dysfunction? 
Venue:    Theater A, George R. Brown Convention Center, Houston, Texas 


About AEZS-130

AEZS-130, a ghrelin agonist, is a novel orally-active small molecule that stimulates the secretion of growth hormone. The Company has completed a Phase 3 trial for use as an oral diagnostic test for AGHD. AEZS-130 has been granted orphan drug designation by the FDA for use in this indication. Aeterna Zentaris owns the worldwide rights to AEZS-130.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company currently investigating treatments for various unmet medical needs. The Company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. For more information please visit



Investor Relations
Ginette Beaudet Vallieres
Investor Relations Coordinator
(418) 652-8525 ext. 265

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406



Posted: June 2012